Literature DB >> 23573305

Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth.

Xiaolei Wang1, Ximei Chen, Jianping Fang, Changqing Yang.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF)-A and VEGF-C are two important molecules involving in tumor development and metastasis via angiogenesis and lymphangiogenesis. However, the combined effect of VEGF-A and VEGF-C on the growth of gastric cancer (GC) is not clear.
METHODS: The correlations of VEGF-A and VEGF-C expressions with clinicopathologic parameters and prognosis were evaluated in patients with GC. Furthermore, lentivirus-mediated RNA interfering (RNAi) targeting VEGF-A and/or VEGF-C was employed to silence their expressions in SGC7901 GC cell line. Cell proliferation and apoptosis were measured in vitro. Suppressive effect lentivirus-mediated VEGF-A and/or VEGF-C silencing on GC growth was evaluated in GC bearing mice.
RESULTS: The patients with high expression of both VEGF-A and VEGF-C (A+C+) had larger tumor size, higher peritumoral lymphatic vessel density(P-LVD), microvessel density(MVD), lymphatic vessel invasion (LVI), lymph node(LN) metastasis, and worse prognosis than those with low expression of both VEGF-A and VEGF-C (P<0.05). Lentivirus-mediated RNAi significantly reduced the mRNA and protein expression of VEGF-A and VEGF-C in the SGC7901 cells. The Lenti-miRNA-VEGF-A+VEGF-C significantly inhibited the cell proliferation and tumor growth, compared with Lenti-miRNA-VEGF-A or Lenti-miRNA-VEGF-C (P<0.05). In addition, Lenti-miRNA- VEGF-A+VEGF-C markedly lowered the tumor size in vivo in comparison with Lenti-miRNA-VEGF-A or Lenti-miRNA-VEGF-C (P<0.05).
CONCLUSION: Expressions of both VEGF-A and VEGF-C predict worse prognosis of GC patients. Combined silencing of VEGF-A and VEGF-C markedly suppresses cancer growth than silencing of VEGF-A or VEGF-C. Thus, to inhibit the expressions of VEGF-A and VEGF-C may become a novel strategy for the treatment of GC.

Entities:  

Keywords:  Vascular endothelial growth factor-A; gastric cancer; prognosis; tumor growth; vascular endothelial growth factor-C

Mesh:

Substances:

Year:  2013        PMID: 23573305      PMCID: PMC3606848     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma.

Authors:  Shigang Ding; Chenggang Li; Sanren Lin; Yajing Han; Yu Yang; Ying Zhang; Lina Li; Liya Zhou; Shant Kumar
Journal:  Oncol Rep       Date:  2007-02       Impact factor: 3.906

2.  VEGF significance in peritoneal recurrence from gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Shojiro Yano; Motoshi Miyagi; Takuya Imaizumi; Jinryo Takeda; Kazuo Shirouzu
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

3.  Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody, D2-40.

Authors:  Yutaka Yonemura; Yoshio Endou; Kayoko Tabachi; Taiichi Kawamura; Hyo-Yung Yun; Toru Kameya; Isamu Hayashi; Etsurou Bandou; Takuma Sasaki; Masahiro Miura
Journal:  Hum Pathol       Date:  2006-07-20       Impact factor: 3.466

4.  Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer.

Authors:  Yutaka Yonemura; Yoshio Endo; Kayoko Tabata; Taiichi Kawamura; Hyo-Yung Yun; Etsurou Bandou; Takuma Sasaki; Masahiro Miura
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

5.  Prognostic significance of vascular endothelial growth factor D in gastric carcinoma.

Authors:  Atsuo Shida; Shuichi Fujioka; Yoshio Ishibashi; Katsutoshi Kobayashi; Hiroshi Nimura; Norio Mitsumori; Yutaka Suzuki; Makio Kawakami; Mitsuyoshi Urashima; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

6.  Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.

Authors:  Meit A Björndahl; Renhai Cao; Jeremy B Burton; Ebba Brakenhielm; Piotr Religa; Dagmar Galter; Lily Wu; Yihai Cao
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

7.  High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer.

Authors:  Takashi Hachisuka; Michihiro Narikiyo; Yukishige Yamada; Hirofumi Ishikawa; Masato Ueno; Hideki Uchida; Ryo Yoriki; Yuichirou Ohigashi; Katsuhiko Miki; Hidetoshi Tamaki; Takashi Mizuno; Yoshiyuki Nakajima
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

8.  Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.

Authors:  M-A Shibata; J Morimoto; E Shibata; Y Otsuki
Journal:  Cancer Gene Ther       Date:  2008-07-25       Impact factor: 5.987

9.  Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis.

Authors:  R A A Mohammed; A Green; S El-Shikh; E C Paish; I O Ellis; S G Martin
Journal:  Br J Cancer       Date:  2007-03-13       Impact factor: 7.640

10.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

Authors:  C Fondevila; J P Metges; J Fuster; J J Grau; A Palacín; A Castells; A Volant; M Pera
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  31 in total

1.  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.

Authors:  Qiaohong Wang; Jingze Gao; Wen Di; Xia Wu
Journal:  Cancer Immunol Immunother       Date:  2020-04-28       Impact factor: 6.968

2.  Clinical value of TV-CDS combined with serum tumor markers in diagnosis of ovarian cancer.

Authors:  Chunying Yu; Ting Dou; Yun Liu; Ruirong Liu
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

3.  Microvascular density and endothelial area correlate with Ki-67 proliferative index in surgically-treated pancreatic ductal adenocarcinoma patients.

Authors:  Michele Ammendola; Rosario Sacco; Ilaria Marech; Giuseppe Sammarco; Valeria Zuccalà; Maria Luposella; Rosa Patruno; Marcella Giordano; Eustachio Ruggieri; Nicola Zizzo; Cosmo Damiano Gadaleta; Girolamo Ranieri
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

4.  A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Authors:  Domenico Ciliberto; Nicoletta Staropoli; Francesca Caglioti; Simona Gualtieri; Lucia Fiorillo; Silvia Chiellino; Antonina Maria De Angelis; Francesco Mendicino; Cirino Botta; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2015-06-10       Impact factor: 4.742

5.  Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Authors:  Didier Meulendijks; Laurens V Beerepoot; Henk Boot; Jan Willem B de Groot; Maartje Los; James E Boers; Steven A L W Vanhoutvin; Marco B Polee; Aart Beeker; Johanna E A Portielje; Robert S de Jong; Swan H Goey; Maria Kuiper; Karolina Sikorska; Jos H Beijnen; Margot E Tesselaar; Jan H M Schellens; Annemieke Cats
Journal:  Invest New Drugs       Date:  2015-12-08       Impact factor: 3.850

6.  Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients.

Authors:  Angelica Petrillo; Maria Maddalena Laterza; Giuseppe Tirino; Luca Pompella; Annalisa Pappalardo; Jole Ventriglia; Beatrice Savastano; Annamaria Auricchio; Michele Orditura; Fortunato Ciardiello; Gennaro Galizia; Ferdinando De Vita
Journal:  J Gastrointest Oncol       Date:  2019-04

7.  Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A.

Authors:  Hongxia Chen; Lingmin Li; Shaojun Wang; Yupeng Lei; Qi Ge; Nonghua Lv; Xiaodong Zhou; Changyan Chen
Journal:  Oncotarget       Date:  2014-12-15

8.  Mesenchymal Stem Cells Differentiate to Endothelial Cells Using Recombinant Vascular Endothelial Growth Factor -A.

Authors:  Mohsen Khaki; Ali Hatef Salmanian; Hamid Abtahi; Ali Ganji; Ghasem Mosayebi
Journal:  Rep Biochem Mol Biol       Date:  2018-04

9.  Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.

Authors:  Qiaoling Sun; Jinghong Zhou; Zheng Zhang; Mingchuan Guo; Junqing Liang; Feng Zhou; Jingwen Long; Wei Zhang; Fang Yin; Huaqing Cai; Haibin Yang; Weihan Zhang; Yi Gu; Liang Ni; Yang Sai; Yumin Cui; Meifang Zhang; Minhua Hong; Junen Sun; Zheng Yang; Weiguo Qing; Weiguo Su; Yongxin Ren
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.

Authors:  Shuai Liu; Lu Lu; Feng Pan; Chunsheng Yang; Jing Liang; Jinfeng Liu; Jian Wang; Rong Shen; Fu-Ze Xin; Nan Zhang
Journal:  Oncol Res       Date:  2022-01-21       Impact factor: 4.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.